Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. - Test2 - elhamkhani - TriplyDB

Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry.

Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry.

http://www.wikidata.org/entity/Q33819083

about

Regulation of TAZ in cancer G Protein-Coupled Receptors in Cancer Uveal melanoma as a target for immune-therapy Mechanisms of Hippo pathway regulation Emerging role of Hippo pathway in gastric and other gastrointestinal cancers Upcoming translational challenges for uveal melanoma Current State of Animal (Mouse) Modeling in Melanoma Research MST kinases in development and disease Targeting the Hippo Signaling Pathway for Tissue Regeneration and Cancer Therapy YAP and TAZ: a nexus for Hippo signaling and beyond ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer Multiparametric Analysis of Cell Shape Demonstrates that β-PIX Directly Couples YAP Activation to Extracellular Matrix Adhesion Uveal melanoma: epidemiology, etiology, and treatment of primary disease.Uveal melanoma: From diagnosis to treatment and the science in between.Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT).A reciprocal regulatory loop between TAZ/YAP and G-protein Gαs regulates Schwann cell proliferation and myelination.ZEB1 Regulates Multiple Oncogenic Components Involved in Uveal Melanoma Progression.The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma in vitro and in vivo.Systematic genomic and translational efficiency studies of uveal melanoma.Oncotargeting G proteins: The Hippo in the room.Biology of advanced uveal melanoma and next steps for clinical therapeutics.Competing to coordinate cell fate decisions: the MST2-Raf-1 signaling device FGF8 promotes colorectal cancer growth and metastasis by activating YAP1.Disease implications of the Hippo/YAP pathway.Netrin-1 exerts oncogenic activities through enhancing Yes-associated protein stability.G Protein-Coupled Receptor and RhoA-Stimulated Transcriptional Responses: Links to Inflammation, Differentiation, and Cell Proliferation.Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation.A miR-130a-YAP positive feedback loop promotes organ size and tumorigenesis.The emerging roles of YAP and TAZ in cancer RAC-LATS1/2 signaling regulates YAP activity by switching between the YAP-binding partners TEAD4 and RUNX3.The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression.Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration.Epidermal loss of Gαq confers a migratory and differentiation defect in keratinocytes The Hippo pathway effectors YAP and TAZ promote cell growth by modulating amino acid signaling to mTORC1.YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage.Myocardin-Related Transcription Factor A and Yes-Associated Protein Exert Dual Control in G Protein-Coupled Receptor- and RhoA-Mediated Transcriptional Regulation and Cell Proliferation.Kaposi sarcoma-associated herpesvirus promotes tumorigenesis by modulating the Hippo pathway.Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway Class III-specific HDAC inhibitor Tenovin-6 induces apoptosis, suppresses migration and eliminates cancer stem cells in uveal melanoma

P2860

Q26740462-89BC69B9-25E0-4FD7-AB9F-FF37600780AB Q26741203-2F6C0BED-9822-4001-BE55-3FCB33064E43 Q26747519-80DBC607-CB5C-4DC0-8D5C-50B66115C39C Q26771285-32B55411-4BAD-4189-9944-769A2CBBF489 Q26774473-1E678751-584D-463A-B259-2FE93FEBB236 Q26778535-7CE99806-DBC4-44FC-9208-D1CABCEC87BF Q26781652-200DEB6F-722B-421E-BA62-8E53307C3143 Q26787040-ADD9B720-BF41-4427-BDB9-478BB320C0E6 Q28078129-42393102-E976-4273-9371-5D98790DC602 Q28085636-B5F27263-C43F-4157-A674-ECCF1A1D3179 Q28115305-B768D197-962C-4A0B-9934-4947ED09D7C6 Q28269498-759F36D3-931D-4121-A640-90EC8B35C6EF Q28817567-B2163FF1-089A-47EA-B920-2B90B811251F Q30235934-1FECF1CA-2507-4C5C-A4D8-EED0453811F9 Q30251762-F48DF9E7-CB64-4AC9-943D-652CAB40BA15 Q30384829-B1B9A622-B0F0-4AF2-8071-D746CDEFB5FE Q33629988-B4C174DD-7A16-4509-AD5B-963D6B1B62CC Q33671316-323F3DF7-E26D-4178-A018-0D1A0FE7B5C8 Q33703068-6E5B48B1-5970-4ACE-97C3-29DFB7052A76 Q33778295-98639312-96D9-4473-A67F-9E71E9AA927F Q34957108-AE75753F-1D61-4112-9D13-D9B6DF835BA3 Q35079709-9D460486-F5BC-4A7B-9F6E-D3B897D32FF4 Q35158033-85E093A7-08E5-466F-9839-2F665F6B0E8A Q35176181-49206B1E-A850-4E97-8406-E43557E7BF06 Q35269102-AD9AE9A6-C603-4649-9995-9571191CF483 Q35740352-42530A0C-302A-459F-AA11-F1BC2C926E10 Q35745964-F6D138F3-0F7F-4A18-9602-CA1DC452B2B6 Q35868895-6D92D921-6151-4A11-827C-38712F828B97 Q36027005-EE088167-ACC8-40D7-8647-D300F8C37B77 Q36035567-E372FCF6-9360-47A7-A319-1A8EDEBE0811 Q36079567-8205402B-5FE0-4711-8FE8-E6C6DADE5F86 Q36278724-469C73F5-3C4B-4006-ACBE-04E62042315B Q36288449-AAB75679-9794-4FEF-830F-26224C351760 Q36310676-9B3DEFEC-9174-4851-B318-AC0288F55FF3 Q36350091-53690424-06D3-4F14-9787-3A765A554161 Q36414976-57B943DA-8F50-4D3C-A504-76CF4C3E56B9 Q36434018-F7E80F35-2DAF-477D-A235-C9A0C393710F Q36486893-7FDDF521-126C-46FE-B085-A724C3712799 Q36546559-944FE71F-F6B3-477E-9571-42D956249802 Q36651002-07CCD901-E474-4C77-9D65-9D12ED74E4E8

P2860

Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry.

http://www.wikidata.org/entity/Q33819083

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Hippo-independent activation o ...... ho GTPase signaling circuitry.

@ast

Hippo-independent activation o ...... ho GTPase signaling circuitry.

@en

type

label

Hippo-independent activation o ...... ho GTPase signaling circuitry.

@ast

Hippo-independent activation o ...... ho GTPase signaling circuitry.

@en

prefLabel

Hippo-independent activation o ...... ho GTPase signaling circuitry.

@ast

Hippo-independent activation o ...... ho GTPase signaling circuitry.

@en

P1433

Q33819083-3D28E263-0613-4479-B75F-B19A9D82A6EB

P1476

Q33819083-C3F1C2E0-FAFC-4EAE-BF67-01ABC4C10BC4

P2093

Q33819083-05FED702-7A60-4397-8228-9F60A89E5122

Q33819083-39C46380-34AF-4D39-8EF1-D49DCD744BE0

Q33819083-5AED24D6-EA91-4341-A5AF-7DAF9F6BBE19

Q33819083-5EDF7D0E-5E2E-41C7-8AC6-B4635B2FF8E8

Q33819083-8C21670D-D852-4C29-B328-CF911E16D2C1

Q33819083-A97B25CA-6F8A-43E2-808F-72A32C0AD154

Q33819083-BEA7FF02-4EFA-46AE-A1D4-1DF664DD77CE

P2860

Q33819083-03BD1D79-E35B-4EE0-AF8C-AC4E729FE1D8

Q33819083-03CAA53F-6E0C-4EB8-A41B-612ABC6C85E2

Q33819083-0BCFA077-C248-4FB4-9C61-5B8970C3CBDE

Q33819083-32EB5517-FC0E-422A-90DE-7A52E6ACA25B

Q33819083-33FBE30D-5CD5-4938-84CE-00A342058F57

Q33819083-3ADD340F-B65B-4A13-BBE4-351F8F19281A

Q33819083-3B2FD72B-9CAE-4972-986D-CE7513ED6215

Q33819083-4020FD97-92BE-41F2-A4BA-1B490475A569

Q33819083-4216A587-CF0D-4DA7-A2A9-9F735D12E4D7

Q33819083-488A58E7-CAC1-4780-AC01-79125BB21ACA

P304

Q33819083-DE7AC2AE-4869-484E-BBDC-C8F1BC60EB2E

P31

Q33819083-AE955E9E-A616-4158-8FFB-0B60573EF984

P356

Q33819083-01686BE2-AB7F-4208-9D18-AACCD15782FF

P433

Q33819083-41BC2E79-ECBF-424E-B1D9-1ACA3D639FAB

P478

Q33819083-7A2BA62D-82FB-4C2B-B8B5-0F6F37EF72A7

P50

Q33819083-9B849220-8513-4CD7-ACB3-C5F92B1E7183

Q33819083-9CDD9C4F-55A2-41A6-ADCF-3ABF08865A4D

Q33819083-B78B636B-BF2A-4932-A97C-655BA12DE445

Q33819083-C6BF3BD0-FB3E-47AB-A633-2D9D603079A6

Q33819083-DEE1C1F8-862B-4B20-94E6-3FC735FD5961

P577

Q33819083-DC3A6650-23FC-4B5C-8A93-FD672B2854FC

P698

Q33819083-0A491998-A43A-41FF-B309-4EC60DCA4CC8

P932

Q33819083-D020F387-9F9C-4145-9681-0A1C70365121

P356

J.CCR.2014.04.016

P1433

P1476

Hippo-independent activation o ...... rho GTPase signaling circuitry

@en

P2093

Akrit Sodhi

http://www.w3.org/2001/XMLSchema#string

Alfredo A Molinolo

http://www.w3.org/2001/XMLSchema#string

Bruce R Ksander

http://www.w3.org/2001/XMLSchema#string

Glenn Merlino

http://www.w3.org/2001/XMLSchema#string

Maria Sol Degese

http://www.w3.org/2001/XMLSchema#string

Qianming Chen

http://www.w3.org/2001/XMLSchema#string

Xiaodong Feng

http://www.w3.org/2001/XMLSchema#string

P2860

Yap1 acts downstream of α-catenin to control epidermal proliferation

Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling

Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control

Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2

Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein

Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP

The hippo signaling pathway in development and cancer

Structures of YAP protein domains reveal promising targets for development of new cancer drugs

Hippo pathway-independent restriction of TAZ and YAP by angiomotin

Mutations in GNA11 in uveal melanoma

P304

831-845

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CCR.2014.04.016

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

Ramiro Iglesias-Bartolome

J. Silvio Gutkind

Murilo W Rodrigues

P577

2014-05-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24882515

http://www.w3.org/2001/XMLSchema#string

P932

4074519

http://www.w3.org/2001/XMLSchema#string